GI Symposium data underscores pelareorep's clinical benefit in anal and pancreatic cancers Pelareorep featured in Key Opinion ...

A healthy 39-year-old Manchester resident, who thought his constant bloating and diarrhoea were due to food intolerance, was diagnosed with bowel cancer, which had a 7 am tumour near his stomach. Rob ...

Incyte Corp.’s Zynyz (retifanlimab-dlwr) has received another U.S. FDA approval and put some distance between it and a 2021 ...

Zynyz is the first and only FDA-approved first-line treatment for adult patients with inoperable locally recurrent or metastatic squamous cell carcinoma of the anal canal.

FDA-approved as the first and only approved first line treatment for advanced squamous cell carcinoma of the anal canal.